<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="366243">
  <stage>Registered</stage>
  <submitdate>1/05/2014</submitdate>
  <approvaldate>20/05/2014</approvaldate>
  <actrnumber>ACTRN12614000535673</actrnumber>
  <trial_identification>
    <studytitle>Diosmin for prevention of Ovarian Hyperstimulation Syndrome in high-risk women undergoing intracytoplasmic sperm injection (ICSI)</studytitle>
    <scientifictitle>Diosmin for prevention of Ovarian Hyperstimulation Syndrome in high-risk women undergoing intracytoplasmic sperm injection (ICSI)</scientifictitle>
    <utrn>U1111-1154-6638</utrn>
    <trialacronym />
    <secondaryid>none</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>infertile women</healthcondition>
    <healthcondition>Ovarian Hyperstimulation Syndrome</healthcondition>
    <healthcondition>PCO (polycystic ovarian syndrome)</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Fertility including in vitro fertilisation</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>In group A, (Diosmin group),  2 tablets every 8 hours Diosmin ( 500mg) will be given from the day of ovum retrieval and for 14 days

drug tablet return used to monitor adherence to treatment</interventions>
    <comparator>In group B, (control group), no thing will be given </comparator>
    <control>Active</control>
    <interventioncode>Prevention</interventioncode>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome> Occurrence of ovarian hyperstimulation syndrome(OHSS)
will be assessed :
	A.	Clinically: 
1.	Abdominal bloating
2.	Mild abdominal pain
3.	Nausea  +/- vomiting
4.	Oliguria
5.	Acute respiratory distress syndrome	
B.		By ultrasound
1.	Ovarian size usually greater than 8 cm
2.	Ultrasound evidence of ascites
C.		Laboratory
1.	haematocrit greater than 45%
2.	Hypoproteinaemia
</outcome>
      <timepoint>will be assessed every two weeks  after retrieval and for 8 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>the pregnancy rate 

 will be assessed by :serum hCG test</outcome>
      <timepoint>Beta sub-unit of hCG (serum hCG test)
was checked 16 days after embryos transfer</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>infertile women with or without polcystic ovarian syndrome  and candidate forICSI with one of the following:

1.	Presence of more than 20 follicles by ultrasound
2.	E2 more than 3000 pg/ml
3.	Retrieval of more than 15 follicles
</inclusivecriteria>
    <inclusiveminage>23</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>48</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>none</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>two hundred women at risk of ovarian hyperstimulation syndrome during ICSI cycles will be randomly scheduled into two equal groups. In group A(100 patients), (Diosmin group),  2 tab every 8 hs Diosmin ( 500mg) will be given from the day of ovum retrieval and for 14 days ; while in group B (100 patients) (control group)no thing will be given

numbered containers will be used</concealment>
    <sequence>odd-numbered patients (group A) will receive 2 tab every 8 hs Diosmin (500mg)(Daflon) will be given from the day of ovum retrieval and for 14 days;
while even-numbered patients (group B) (control group) will recieve no thing

Simple randomisation using coin-tossing.
</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods>Data obtained will be statistically analyzed using The Statistical Package for Social Sciences (SPSS, Chicago, USA) software version 15.0 for Windows. Results will be expressed as mean  +/- SD, numbers and percentages. Means will be compared using the paired students t test while categorical data will be compared using the chi-square test with Yates' continuity correction. A p value of less than 0.05 is considered statistically significant

sample size calculation is according to the following formula:

N = 2Standard deviation X K / E2


*Standard deviation: population of previous literature
*K : constant (7.8) from statistical table
*E2: minimal change in mean that would be clinical

</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>13/02/2014</anticipatedstartdate>
    <actualstartdate>15/02/2014</actualstartdate>
    <anticipatedenddate>8/08/2014</anticipatedenddate>
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Egypt</country>
      <state>Benha city</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>khalid abd aziz mohamed</primarysponsorname>
    <primarysponsoraddress>Benha University, Faculty of Medicine
el saha street
Benha city
Qalubiya Governorate
Egypt
13518</primarysponsoraddress>
    <primarysponsorcountry>Egypt</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Ahmed samy saad</fundingname>
      <fundingaddress>Benha University, Faculty of Medicine
el saha street
Benha city
Qalubiya Governorate
Egypt
13518</fundingaddress>
      <fundingcountry>Egypt</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>khalid abd aziz mohamed</fundingname>
      <fundingaddress>Benha University, Faculty of Medicine
el saha street
Benha city
Qalubiya Governorate
Egypt
13518</fundingaddress>
      <fundingcountry>Egypt</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Ahmed samy saad</sponsorname>
      <sponsoraddress>Benha University, Faculty of Medicine
el saha street
Benha city
Qalubiya Governorate
Egypt
13518</sponsoraddress>
      <sponsorcountry>Egypt</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Objectives: To assess the effecacy of oral Diosmin in the prevention of ovarian hyperstimulation syndrome (OHSS) in high-risk women underwent intracytoplasmic sperm injection (ICSI). 
Study design: Prospective randomized controlled clinical trial. 
Patients and Methods: two hundred women at risk of ovarian hyperstimulation syndrome during ICSI cycles will be randomly scheduled into two equal groups. In group A, (Diosmin group),  2 tab every 8 hs Diosmin ( 500mg) will be given from the day of ovum retrieval ; while in group B (control  group), no thing will be given. The main outcome measures were rates and grades of OHSS, and the pregnancy rate in both groups.
</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Department of Obstetrics and Gynecology, Benha University Hospitals, and private practice </ethicname>
      <ethicaddress>Benha University, Faculty of Medicine
el saha street
Benha city
Qalubiya Governorate
Egypt
13518</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Egypt</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>khalid  abd aziz mohamed</name>
      <address>Benha University, Faculty of Medicine
el saha street
Benha city
Qalubiya Governorate
Egypt
13518</address>
      <phone>+201281469651</phone>
      <fax />
      <email>dr.khalidkhader77@yahoo.com</email>
      <country>Egypt</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>ahmed samy saad</name>
      <address>Benha University, Faculty of Medicine
el saha street
Benha city
Qalubiya Governorate
Egypt
13518</address>
      <phone>+201281469651</phone>
      <fax />
      <email>drahmedsaad@live.com</email>
      <country>Egypt</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>khalid  abd aziz mohamed</name>
      <address>Benha University, Faculty of Medicine
el saha street
Benha city
Qalubiya Governorate
Egypt
13518</address>
      <phone>+201281469651</phone>
      <fax />
      <email>dr.khalidkhader77@yahoo.com</email>
      <country>Egypt</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>khalid  abd aziz mohamed</name>
      <address>Benha University, Faculty of Medicine
el saha street
Benha city
Qalubiya Governorate
Egypt
13518</address>
      <phone>+201281469651</phone>
      <fax />
      <email>dr.khalidkhader77@yahoo.com</email>
      <country>Egypt</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>